Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Roginolisib - iOnctura

Next Previous
X
Search
Drug Profile

Roginolisib - iOnctura

Alternative Names: IOA-244

Latest Information Update: 16 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cancer Research Technology; GSK; Merck & Co
  • Developer iOnctura
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveal melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Uveal melanoma
  • Phase II Chronic lymphocytic leukaemia; Myelofibrosis; Non-small cell lung cancer; Peripheral T-cell lymphoma
  • Phase I/II Haematological malignancies; Solid tumours
  • Phase I Malignant melanoma; Mesothelioma; Non-Hodgkin's lymphoma

Most Recent Events

  • 11 Dec 2024 Efficacy and adverse events data from a phase I trial in Uveal melanoma released by iOnctura
  • 11 Dec 2024 iOnctura completes the phase I trial in Cancer (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy) in Italy, United Kingdom (PO)
  • 11 Dec 2024 iOnctura plans a phase II OCULE-01 trial for Uveal Melanoma (Late-stage disease, metastatic disease, second-line or greater therapy) (PO) in December 2024 (NCT06717126)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top